I want a new drug: G-protein-coupled receptors in drug development

Drug Discovery Today

Volumn 11, Issue 11-12, 2006, Pages 481-493

  Schlyer, Sabine ^a   Horuk, Richard ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMLODIPINE BESYLATE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CLOPIDOGREL; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; FLUTICASONE PROPIONATE PLUS SALMETEROL; G PROTEIN COUPLED RECEPTOR; GABAPENTIN; GONADORELIN ANTAGONIST; KR 31016; L 163017; L 742042; L 746072; LANSOPRAZOLE; LOSARTAN POTASSIUM; OLANZAPINE; OXYCODONE; PANTOPRAZOLE; PRAVASTATIN; PROPRANOLOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; ROFECOXIB; SERTRALINE; SIMVASTATIN; UCB 35625; UNINDEXED DRUG; VENLAFAXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANGINA PECTORIS; ARTERIOSCLEROSIS; BINDING AFFINITY; CANCER; CONGESTIVE HEART FAILURE; DRUG BINDING SITE; DRUG DESIGN; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; HEART DISEASE; HUMAN; HYPERTENSION; MOLECULAR MODEL; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REVIEW; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646526072     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.04.008     Document Type: Review

References (91)

1. Gershengorn M.C., and Osman R. Minireview: Insights into G protein-coupled receptor function using molecular models. Endocrinology 142 (2001) 2-10
2. Bissantz C., et al. High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening. J. Chem. Inf. Comput. Sci. 44 (2004) 1162-1176
3. Perez D.M. The evolutionarily triumphant G-protein-coupled receptor. Mol. Pharmacol. 63 (2003) 1202-1205
4. Fredriksson R., and Schioth H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. 67 (2005) 1414-1425
5. Klein P.S., et al. A chemoattractant receptor controls development in Dictyostelium discoideum. Science 241 (1988) 1467-1472
6. Versele M., et al. Sex and sugar in yeast: two distinct GPCR systems. EMBO Rep. 2 (2001) 574-579
7. Horn F., et al. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res. 31 (2003) 294-297
8. Foord S.M., et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol. Rev. 57 (2005) 279-288
9. Venter J.C., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
10. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-921
11. Reed R.R. After the holy grail: establishing a molecular basis for mammalian olfaction. Cell 116 (2004) 329-336
12. Adler E., et al. A novel family of mammalian taste receptors. Cell 100 (2000) 693-702
13. Okada T., et al. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 26 (2001) 318-324
14. Brown E.M., et al. The extracellular calcium-sensing receptor: its role in health and disease. Annu. Rev. Med. 49 (1998) 15-29
15. Vernier P., et al. An evolutionary view of drug-receptor interaction: the bioamine receptor family. Trends Pharmacol. Sci. 16 (1995) 375-381
16. Brown A.J., et al. A family of fatty acid binding receptors. DNA Cell Biol. 24 (2005) 54-61
17. Lujan R., et al. Glutamate and GABA receptor signalling in the developing brain. Neuroscience 130 (2005) 567-580
18. Janecka A., et al. Opioid receptors and their ligands. Curr. Top. Med. Chem. 4 (2004) 1-17
19. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 12 (2001) 313-335
20. Fredholm B.B., et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
21. Chun J., et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54 (2002) 265-269
22. Brink C., et al. International Union of Pharmacology. XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol. Rev. 56 (2004) 149-157
23. Kostenis E. A glance at G-protein-coupled receptors for lipid mediators: a growing receptor family with remarkably diverse ligands. Pharmacol. Ther. 102 (2004) 243-257
24. He W., et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429 (2004) 188-193
25. Revankar C.M., et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
26. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
27. Civelli O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. 26 (2005) 15-19
28. Palczewski K., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289 (2000) 739-745
29. Black J.W. Ahlquist and the development of beta-adrenoceptor antagonists. Postgrad. Med. J. 52 Suppl. 4 (1976) 11-13
30. Chafin C.C., et al. Beta-blockers after myocardial infarction: do benefits ever outweigh risks in asthma?. Cardiology 92 (1999) 99-105
31. Betti L., et al. Alpha(1)-adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives. J. Med. Chem. 45 (2002) 3603-3611
32. Tagat J.R., et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)- [4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J. Med. Chem. 44 (2001) 3343-3346
33. Mirzadegan T., et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275 (2000) 25562-25571
34. Forbes I.T., et al. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. Bioorg. Med. Chem. Lett. 10 (2000) 1803-1806
35. Hesselgesser J., et al. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. 273 (1998) 15687-15692
36. Hale J.J., et al. 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg. Med. Chem. Lett. 11 (2001) 1437-1440
37. Finke P.E., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 11 (2001) 265-270
38. Roche O., et al. Development of a virtual screening method for identification of 'frequent hitters' in compound libraries. J. Med. Chem. 45 (2002) 137-142
39. Cascieri M.A., et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J. Biol. Chem. 274 (1999) 8694-8697
40. Sachais B.S., et al. Molecular basis for the species selectivity of the substance P antagonist CP-96 345. J. Biol. Chem. 268 (1993) 2319-2323
41. Beinborn M., et al. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature 362 (1993) 348-350
42. Maconi A., et al. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. J. Med. Chem. 45 (2002) 3579-3582
43. Reinhart G.J., et al. Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus. J. Biol. Chem. 279 (2004) 34115-34122
44. Ji H., et al. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9240-9244
45. Oksenberg D., et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360 (1992) 161-163
46. Kelly J., et al. US pharma: notes from the IRA conference-future drugs appearing on the horizon (2002), Goldman Sachs
47. Archer E., et al. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors?. Trends Pharmacol Sci. 24 (2003) 36-40
48. Bissantz C., et al. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets?. Proteins 50 (2003) 5-25
49. Doranz B.J., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996) 1149-1158
50. Ribeiro S., and Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol. Ther. 107 (2005) 44-58
51. Dragic T., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5639-5644
52. Paterlini M.G. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys. J. 83 (2002) 3012-3031
53. Kazmierski W., et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg. Med. Chem. 11 (2003) 2663-2676
54. Castonguay L.A., et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42 (2003) 1544-1550
55. Liu S., et al. Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies. J. Mol. Model. (Online) 9 (2003) 329-336
56. Seibert C., and Sakmar T.P. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des. 10 (2004) 2041-2062
57. Xu Y., et al. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor. Bioorg. Med. Chem. 12 (2004) 6193-6208
58. Govaerts C., et al. The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J. Biol. Chem. 276 (2001) 13217-13225
59. Govaerts C., et al. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem. 278 (2003) 1892-1903
60. Ballesteros J.A., and Weinstein H. Integrated Methods for the Construction of Three Dimensional Models and Computational Probing of Structure-Function Relations in G-protein Coupled Receptors (1995), Academic Press
61. Becker O.M., et al. G protein-coupled receptors: in silico drug discovery in 3D. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11304-11309
62. Vaidehi N., et al. Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12622-12627
63. Freddolino P.L., et al. Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2736-2741
64. Kalani M.Y., et al. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3815-3820
65. Fong T.M., and Strader C.D. Functional mapping of the ligand binding sites of G-protein coupled receptors. Med. Res. Rev. 14 (1994) 387-399
66. Liapakis G., et al. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J. Biol. Chem. 275 (2000) 37779-37788
67. Shi L., et al. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277 (2002) 40989-40996
68. Furse K.E., and Lybrand T.P. Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J. Med. Chem. 46 (2003) 4450-4462
69. Shacham S., et al. PREDICT modeling and in-silico screening for G-protein coupled receptors. Proteins 57 (2004) 51-86
70. Evers A., and Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 48 (2005) 1088-1097
71. Vainio H., and Morgan G. Aspirin for the second hundred years: new uses for an old drug. Pharmacol. Toxicol. 81 (1997) 151-152
72. Katler E., and Weissmann G. Steroids, aspirin, and inflammation. Inflammation 2 (1977) 295-307
73. Serhan C.N., et al. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10 (1996) 1147-1158
74. de Gasparo M., et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52 (2000) 415-472
75. Sakurai T., et al. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 13 (1992) 103-108
76. Murugesan N., et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J. Med. Chem. 45 (2002) 3829-3835
77. Murugesan N., et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem. 48 (2005) 171-179
78. Dascal D., et al. Shared determinants of receptor binding for subtype selective, and dual endothelin-angiotensin antagonists on the AT1 angiotensin II receptor. FEBS Lett. 423 (1998) 15-18
79. Lee T., et al. Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics. Bioorg. Med. Chem. Lett. 13 (2003) 767-770
80. Klabunde, T. and Jager, R. Chemogenomics approaches to GPCR lead finding, In Chemical Genomics: Small Molecule Probes to Study Cellular Function (Vol. 57), Springer Verlag (in press)
81. de Mendonca F.L., et al. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. 280 (2005) 4808-4816
82. Vedani A., et al. Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR. J. Med. Chem. 48 (2005) 1515-1527
83. Naya A., et al. Structure-activity relationships of 2-(benzothiazolylthio)acetamide class of CCR3 selective antagonist. Chem. Pharm. Bull. (Tokyo) 51 (2003) 697-701
84. Sabroe I., et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275 (2000) 25985-25992
85. Bridger, G.J. et al. (2002) Chemokine receptor binding heterocyclic compounds. In World (PCT) Patent WO-00222599
86. Princen K., et al. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol. 78 (2004) 12996-13006
87. Morphy R., et al. From magic bullets to designed multiple ligands. Drug Discov. Today 9 (2004) 641-651
88. Morphy R., and Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48 (2005) 6523-6543
89. Frantz S. Drug discovery: playing dirty. Nature 437 (2005) 942-943
90. Murugesan N., et al. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2′-amino-N-(3,4-dimethyl-5-isoxazolyl)-4′-(2-methylpropyl)[1,1′-biphenyl]-2-sulfonamide (BMS-187308). J. Med. Chem. 41 (1998) 5198-5218
91. Murugesan N., et al. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4′-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists. J. Med. Chem. 43 (2000) 3111-3117